Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relovair Data Raises Respiratory Stakes For GSK And Theravance

Executive Summary

Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies

Advertisement

Related Content

COPD Market Snapshot: New Products, Limited Differentiation
For Theravance, A Big Year Gets Off To A Strong Start
FDA Panel Will Weigh Mixed Efficacy Data For GSK’s Breo Ellipta In COPD
GSK’s COPD Drug Gets A New Name (Breo) But May Face Familiar Challenges At FDA Panel
GSK/Theravance Breathing Easy: Once-Daily COPD Combo Expected To Meet Regulatory Standards
Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
FDA Supersizes Its Order For LABA Safety Studies
GSK Boosts Stake In Theravance, An Apparent Nod To The Biotech's Respiratory Portfolio
Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS054110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel